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HIV-1The extraordinarily high level of genetic variation of HIV-1 env genes poses a challenge to obtain antibodies
that cross-react with multiple subtype Env glycoproteins. To determine if cross-reactive monoclonal
antibodies (mAbs) to highly conserved epitopes in HIV-1 envelope glycoproteins can be induced, we
immunized mice with wild-type or consensus HIV-1 Env proteins and characterized a panel of ten mAbs that
reacted with varying breadth to subtypes A, B, C, D, F, G, CRF01_AE, and a highly divergent SIVcpzUS Env
proteins by ELISA and Western blot analysis. Two mAbs (3B3 and 16H3) cross-reacted with all tested Env
proteins, including SIVcpzUS Env. Surface plasmon resonance analyses showed both 3B3 and 16H3 bound
Env proteins with high afﬁnity. However, neither neutralized primary HIV-1 pseudoviruses. These data
indicate that broadly reactive non-neutralizing monoclonal antibodies can be elicited, but that the conserved
epitopes that they recognize are not present on functional virion trimers. Nonetheless, such mAbs represent
valuable reagents to study the biochemistry and structural biology of Env protein oligomers.
© 2009 Elsevier Inc. All rights reserved.Introduction
One of the hallmarks of HIV-1 is its extraordinary variability. Based
on phylogenetic analysis, the most prevalent group M viruses are
classiﬁed into nine subtypes (Kuiken et al., 2008; Robertson et al.,
2000). Some of these subtypes have recombined and generated
circulating recombinant forms (CRFs) (Robertson et al., 2000). Some
CRFs have become predominant in certain geographic areas, e.g.,
CRF01_AE in South and Southeast Asia and CRF02_AG in West Africa
(Hemelaar et al., 2006; Osmanov et al., 2002). Although considerable
efforts have been devoted to the development of diagnostic tests that
can detect all HIV-1 subtypes, the high level of genetic variability, Research Drive, Duke Human
ham, NC 27710, USA. Fax: +1
ll rights reserved.renders the generation of reagents that reliably detect all divergent
viruses challenging (Lal, Chakrabarti, and Yang, 2005; Peeters, Toure-
Kane, and Nkengasong, 2003; Taylor et al., 2008).
The env gene is one of the most divergent genes in the HIV-1
genome (Gaschen et al., 2002). The Env glycoprotein mediates virion
attachment and fusion to host cells and is the only viral protein that
can elicit neutralizing antibodies. It is important to identify mAbs that
recognize conserved regions in the HIV envelope to generate reagents
for virion detection. Moreover, the development of mAbs that bind all
HIV-1 subtypes would facilitate the development of diagnostic tests
targeted at body ﬂuid soluble Env detection. Cross-reactivity of HIV-1-
infected patient sera to Env proteins from different subtypes has been
observed, suggesting recognition of conserved epitopes (Gao et al.,
2003; Gao et al., 2005; Gilljam et al., 1999; Moore et al., 1996; Moore
et al., 1994). Thus far, only a handful of broadly reactive monoclonal
antibodies (mAbs) have been isolated, some of which (b12, 2G12, 2F5,
and 4E10/Z13) are also capable of neutralizing a broad spectrum of
viruses (Binley et al., 2004; Lin and Nara, 2007; Moore et al., 1994;
Table 1
Cross-reactivity of mouse monoclonal antibodies to multiple subtype envelope glycoproteins.
Immunogen mAb Subtype A Subtype B Subtype C Subtype consensus Group M consensus SIVcpz
92RW020 HXB2/Bal 89.6 JRFL 97ZA012 DU123 95ZM651 A1.con B.con C.con CON-S US-1
C_97ZA012 18A7 − − − + + + − − − − + −
19C12 + − − + ++ − − − + − + −
15E9 ++ + + ++ ++++ + + + + + ++ +
16H3 +++ ++++ ++++ +++ ++++ +++ +++ +++ ++++ +++ +++ +++
17G12 + + + + +++ + − + + + + +
18F11 − − − + + − − − − + + −
3B3 +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++ +++
8H3 +++ − ++ ++ ++++ ++++ ++++ + ++ ++++ +++ −
CON6 13D5 − ++++ ++++ ++++ +++ +++ ++++ − +++ +++ +++ ++++
13D7 ++ + ++ + + + + ++ + + +++ +
Results were scored as following OD values: −, between 0.0 and b0.25 and b3 fold of background; +, between 0.25 and b1; ++, between 1 and b1.5; +++, between 1.5 and
b2; ++++, ≥2.
92 F. Gao et al. / Virology 394 (2009) 91–98Trkola et al., 1995; Zwick et al., 2001). These rare neutralizing human
mAbs either target glycans on the surface of gp120, bind conforma-
tion-sensitive CD4 binding or induced sites, or bind Env regions close
to the lipid membrane on gp41 (Burton et al., 1994; Moore et al.,
1994; Moulard et al., 2002; Sanders et al., 2002; Trkola et al., 1996;
Zwick et al., 2001). Nonetheless, identiﬁcation and characterization of
additional cross-reactive mAbs, regardless of their neutralizing
capacity, would be helpful to understand the structure and biology
of HIV-1 envelope glycoproteins as immunogens. In this report, we
have produced and characterized ten novel murine mAbs, two of
which cross-react with HIV-1 envelope glycoproteins from all HIV-1
envelope subtypes as well as SIVcpz.Fig. 1. Cross-clade reactivity of mAbs to a panel of diverse HIV-1 envelope proteins. HIV-1 Env
(CRF01_AE), a groupM consensus (CON), and an SIVcpzUS1 (SIV) were tested with newly ch
at the right of the blots. The Env proteins were separated on a reducing 10% SDS–polyacrylam
with ﬂuorescent labeled secondary antibodies (1 μg/mL). The 2F5 and 4E10 epitopes in gpResults
Identiﬁcation of broadly reactive mouse monoclonal antibodies
Hybridoma culture supernatants were screened by ELISA to
identify mAbs that reacted with HIV-1 Env glycoproteins from
multiple subtypes. A total of 12 Env proteins were used as coating
antigens for ELISA screening: 92RW020 (subtype A); HXB2, 89.6, and
JRFL (subtype B); 97ZA012, DU123, and 96ZM651 (subtype C); A1.
con, B.con, and C.con (subtype consensus), CON-S (group M
consensus); and SIVcpzUS. Seventeen hybridoma lines were found
to secret mAbs reacting with autologous Env proteins in miceproteins (100 ng/each) from ﬁve subtypes (A, B, C, D, and F), a circulating recombinant
aracterized mAbs (A) and broadly neutralizing mAbs (B). The names of mAbs are shown
ide gel, blotted onto a nitrocellulose membrane, reacted tomAbs (1 μg/mL), and probed
140 and their reactivity to mAbs are shown (C).
Fig. 2. Binding kinetics analysis of mAbs to HIV-1 Env proteins by surface plasmon resonance. HIV-1 Env gp140 proteins were immobilized to about 1000 RU using amine coupling
chemistry. Positive control V3 mAb F39F was used to assess activity of gp140 proteins following immobilization. Monoclonal Abs were injected at 50 μg/mL for 2 min at 30 μL/min.
For binding kinetics analyses, mAbs were injected at varying concentrations ranging from 1.2 mg/mL to 1.5 μg/mL. Due to the bivalency of themAbs used, binding rate constants and
Kd values were derived from global curve ﬁtting using the “Bivalent Analyte” model and binding Kd was calculated from faster rate constants (ka and kd).
93F. Gao et al. / Virology 394 (2009) 91–98immunized with C_97ZA012 gp140. Among eight cloned mAbs, three
(15E9, 16H3, and 3B3) reacted with all Env proteins tested, while the
ﬁve others exhibited varying levels of cross-reactivity (Table 1). In
CON6 gp140 immunized mice, 21 hybridoma lines were found to
produce mAbs reacting with CON6 gp140 and two (13D5 and 13D7)
were cloned. While 13D7 reacted to all Env proteins, 13D5 did not
react with A_92RW020 and A1.con. This suggested that the 13D5
epitope was not present on subtype A Env glycoproteins. Among all
cloned mAbs, 3B3 and 16H3 showed the strongest ELISA responses to
all proteins tested (Table 1).
Determination of breadth of mAb reactivity by Western blot analysis
To further conﬁrm the cross-reactivity of these mAbs, a panel of
wild-type Env proteins frommore Env subtypes was used forWestern
blot analysis. Ten mAbs that reacted with multiple subtype Env
proteins in ELISA assays were tested against 14 Env proteins from
subtype A (92UG037 and 92RW020), subtype B (JRFL, IIIB and SF162),
subtype C (96ZM651, DU123 and CN5), subtype D (92UG021),
CRF01_AE (93TH975 and CM235), subtype F (93BR029), the group
M consensus (CON6), and SIVcpzUS (Fig. 1). For direct comparison,Table 2
Surface plasmon resonance binding kinetics of mAbs to oligomeric HIV-1 Env gp140 protei
Group mAb JRFL CON
ka kd Kd ka
M−1 s−1
(×103)
s−1
(×10−2)
M
(×10−9)
M−
(×1
Moderate afﬁnity
fast binding
17G12 – – NM 95
8H3 20 6.4 3200 14
High afﬁnity
medium binding
3B3 28 0.77 275 24
16H3 15 0.19 129 11
15E9 – – NM 7.4
Low afﬁnity
slow binding
19C12 – – NM 1
13D5 1.3 4.5 3460 0.8
18A7 – – NM 1.2
13D7 – – NM 5.6
18F11 0.68 0.74 10870 0.8
Positive control
Negative control
F39F 6.3 0.002 380 13
7G9a – – – –
NM: binding too weak to be measured.
a 7G9 mAb did not bind to Env gp140.equal amounts of Env protein (100 ng) were loaded in each gel. As
observed in the ELISA analysis, both 3B3 and 16H3 mAbs showed the
strongest response to all wild-type, groupM consensus, and SIVcpzUS
Env glycoproteins. The intensities of Env bands for subtype A, subtype
F, groupM consensus, and SIVcpzUSwere stronger than those of other
Env proteins. 13D7 also recognized all Env proteins but reacted only
weakly with 6 of the 14 Env proteins tested. 13D5 showed good cross-
reactivity but did not react with subtype A and F Env proteins. This
ﬁnding was consistent with the ELISA results and suggested that the
13D5 epitope was not present in subtype A and F envelope
glycoproteins.
Five other mouse mAbs (17G12, 18A7, 18F11, 8H3, and 19C12)
reacted either weakly with all Env proteins or recognized only a
subset in the panel, again consistent with the ELISA results. 15E9 mAb
was reactive to all Env proteins in ELISA, but only recognized
A_92RW020 in Western blot analysis, suggesting 15E9 react pre-
dominantly with a conformational determinant that was not
preserved in most Env proteins in their denatured state. Similar
results were observed with mAbs 2G12 and 1b12 which recognize
conformation dependent binding sites (Fig. 1B). Both 2F5 and 4E10
recognize linear epitopes near the membrane-proximal externalns.
-S B.con
kd Kd ka kd Kd
1 s−1
03)
s−1
(×10−2)
M
(×10−9)
M−1 s−1
(×103)
s−1
(×10−2)
M
(×10−9)
1 105 16.4 5.4 3305
1.2 710 10 3 2600
0.16 72 26 0.63 238
0.29 260 11.2 0.29 256
0.28 384 9.2 0.29 317
2.4 2450 2 1.4 7000
1.9 2310 0.8 7 8750
4.4 3550 – – NM
3.2 5754 6.6 4 6050
1.8 21770 0.56 6.5 11650
0.15 115 6.5 0.045 69.2
– – – – –
Fig. 3. Detection of Env proteins on cell membrane by ﬂow cytometry. The ﬁrst ﬁve columns show transfected 293T cells labeled with PE-conjugated mAbs to HIV-1 envelope (16H3, 3B3, 13D5, and 2G12). White histograms correspond to
expression of HIV-1 Env on transfected 293T cells (A1.con, B.con, B_MN, B_15313, and B_17779). Grey shaded histogram represents the empty vector (control) transfected cells. The rightmost column show B_MN infected H9 cells labeledwith
unconjugated mAbs and detected with FITC-conjugated secondary antibody. White histograms represent binding to the infected cells, while grey shaded histogram represents binding of the secondary antibody in the absence of primary
antibody. All plots are representative of triplicate samples.
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95F. Gao et al. / Virology 394 (2009) 91–98region, but they only reacted with a few gp140 Env proteins in the
panel due to the amino acid substitutions in the epitopes (Figs. 1B and
C). Interestingly, eight mAbs (3B3, 16H3, 13D5, 13D7, 17G12, 18A7,
18F11 and 19C12) reacted with the highly divergent SIVcpzUS Env
protein. These data indicate conservation of some epitopes following
cross-species transmission from chimpanzees to man (Gao et al.,
1999; Hahn et al., 2000). However, 3B3 and 16H3 mAbs did not react
with SIVmac251 gp120 or SIVmac259 gp130 proteins (not shown).
Characterization of binding kinetics of mAbs to HIV-1 Env gp140
To determine mAb binding kinetics and avidity, each mAb was
characterized by surface plasmon resonance (SPR) with three
distinct oligomeric gp140 proteins: a wild-type subtype B (JRFL), a
group M consensus (CON-S), and a subtype B consensus (B.con).
Marked differences in binding kinetics were observed (Fig. 2). Based
on the relative binding kinetics and Kd (afﬁnity) values, the mAbs
could be classiﬁed into three groups: (i) moderate afﬁnity with fast
binding kinetics (fast on and off rates), (ii) high afﬁnity with
medium binding kinetics (fast on and slow off rates), and (iii) low
afﬁnity with slow binding kinetics (slow on and off rates) (Table 2).
Representatives of each group are shown in Fig. 2. The ﬁrst group of
mAbs (17G12 and 8H3) displayed fast binding kinetics (on and off
rates, ka and kd) and bound more strongly to CON-S (Kd=105 and
710 nM, respectively). While both 8H3 and 17G12 also bound to B.
con with micromolar Kd, only 8H3 bound to B_JRFL (Kd=3.2 μM).
Among the mAbs with slow binding dissociation rate constants
(off rates, kd), the highest binding afﬁnity (lower Kd) was measured
for 3B3, 16H3, and 15E9. MAbs in this group were high-afﬁnity
binders with slow kd values. 3B3, 16H3, and 15E9 bound Env pro-
teins with much slower (about 10-fold when compared to 8H3 and
17G12) kd and with the resulting Kd values ranging from 72 to 384
nM (Table 2 and Fig. 2). More breadth in reactivity was observed
with 3B3 and 16H3, both of which bound to all three Env proteins
strongly. 15E9 was more selective and bound strongly to CON-S and
B.con (Kd=384 nM and 317 nM, respectively) while binding to
B_JRFL gp140 was too weak to be measured.
The third group of mAbs included those that bound weakly to Env
proteins with Kd in micromolar range. The weaker binding Kd of these
mAbs was largely due to slower on rates (Table 2 and Fig. 2). For the
majority of mAbs in this group, binding was preferentially observed
with CON-S and B.con. However, 13D5 and 18F11 also bound to JRFL
(Kd=3.5 μM and 10.9 μM, respectively). Binding of 18F11 to all three
Env proteins was relatively weaker (Kd=21.8 μM, 10.9 μM and
11.7 μM to CON-S, B_JRFL, and B.con, respectively).
Overall, this panel of mAbs bound better with lower binding Kd to
CON-S and B.con when compared to JRFL (Fig. 2 and Table 2). Among
all mAbs, 3B3 bound to Env proteins with higher afﬁnity (Kd=72 nM,
275 nM, and 238 nM for CON-S, JRFL, and B.con, respectively). The
ability of mAbs to bind B_JRFL Env was restricted and the highest
afﬁnity binding was observed with 16H3 and 3B3. Thus among three
Env proteins, both consensus Env proteins (CON-S and B.con) showed
broad reactivity to all testedmAbs, while JRFL was relatively restricted
to only 5 out of 10 mAbs.
Detection of cell surface Env proteins
To determine whether mAbs 3B3, 16H3, and 13D5 could bind Env
proteins on the cell surface, we transfected 293T cells with subtype A1
and C consensus, B_MN (subtype B), and two clinical isolate (subtype
B) env genes (B_15313 and B_17779). 293T cells were treated 48 hrs
after transfection and stained with PE-conjugated cross-reactive
mAbs (3B3, 16H3, and13D5) and one positive control mAb (2G12).
Compared to mock transfected cells, positive reactivity was observed
in 16H3 and 3B3 mAb treated cells, each expressing one of ﬁve
different env genes (Fig. 3). When labeled with 13D5 mAb, cellsexpressing three subtype B Env and a subtype C consensus Env were
reactive compared to mock transfected cells, but as in the ELISA and
Western blot analyses, 13D5 did not recognize the subtype A
consensus Env (Table 1 and Fig. 1). Cells expressing A1.con, B.con,
and B_17779 Env proteins also reacted with the glycan speciﬁc mAb,
2G12. Although the expression levels of Env proteins were not
normalized, our results clearly showed that both 3B3 and 16H3 were
reactive with Env proteins on cells transfected with the subtype A, B,
or C env genes. When tested with H9 cells infected with B_MN, none
of the three mAbs bound Env on the surface of HIV-1 infected T cells,
while the control 2G12 bound well (Fig. 3).
Ability of mAbs to neutralize HIV-1
To determine if mAbs in the cross-reactive panel could neutralize
primary HIV-1 strains, all mAbs (3B3, 16H3, 13D7, 13D5, 17G12, 18A7,
18F11, 8H3, 19C12, and 15E9), other select mAbs (2B9, 7B9, 7G9,
15B10, and 15D6), and two control mAbs (2F5 and 4E10) were tested
in single round pseudovirus neutralization (TZM-bl) assays (Wei et
al., 2002). A total of 15 puriﬁed mAbs were assayed against a panel of
11 tier 1 and tier 2 subtype B and C pseudoviruses (Li et al., 2005,
2006a). None of the cross-reactive mAbs neutralized any pseudo-
viruses at 50 μg/mL, suggesting that the conserved epitopes that they
targeted were not accessible on HIV-1 functional Env proteins.
We then determined whether these mAbs could bind free virus
particles in an ELISA based capture assay. Of 13 tested mAbs, only a
previously described human anti-gp41 immunodominant regionmAb
7B2 (Binley et al., 2000) was able to capture SF162 or BG1168
pseudovirus particles (data not shown). Three previously character-
ized control mAbs (17b, F39F, and 2G12) were also able to capture
virions, and the capture was signiﬁcantly increased when soluble CD4
was added. Taken together, these data suggested that mouse mAbs to
the most cross-reactive HIV-1 Env epitopes did not efﬁciently bind to
native envelope spikes on virions.
Epitope mapping of mAbs
All mAbs in Table 1 were tested against a panel of peptides from
the MPER region, variable loops, and the conserved gp41 immuno-
dominant region. All mAbs were non-reactive with all peptides
studied. In competitive inhibition assays, none of the mAbs blocked
the binding of mAbs 2F5, 2G12, or 1b12 to B_JRFL Env oligomer (data
not shown).
Discussion
Well-characterized mAbs can play an important role in under-
standing of the structure, biology and neutralization epitopes of HIV-1
glycoproteins (Binley et al., 2004; Lin and Nara, 2007; Moore et al.,
1994; Wyatt et al., 1998). In this study, we identiﬁed two broadly
reactive mAbs (3B3 and 16H3) frommice immunized with HIV-1 Env
proteins. They were both cross-reactive at a high afﬁnity to all tested
HIV-1 Env proteins from ﬁve subtypes (A, B, C, D, and F), one
CRF01_AE, and one highly divergent SIVcpzUS – thus, demonstrating
that these epitopes were conserved among HIV-1 subtypes as well as
SIVcpz (Gao et al., 1999; Hahn et al., 2000).
A number of mouse mAbs have been obtained from HIV-1 Env
immunized mice (Abacioglu et al., 1994; Derby et al., 2007; Reeves et
al., 1995; Sugiura et al., 1999). Although many of those were found to
target conserved regions (C1, C2, and C3) or the CD4 binding site in
gp120, cross-clade reactivities were not evaluated. Some were able to
weakly neutralize sensitive tier 1 HIV-1 strains (Derby et al., 2007;
Sugiura et al., 1999). MAbs 2F5, 4E10, 2G12, IgG1b12 (neutralizing),
and A32 (non-neutralizing) are broadly reactive gp120 human mAbs
that have been characterized. SincemAbs 2G12, 1b12, and A32 bind to
highly conformation-sensitive epitopes, they decrease or lose their
96 F. Gao et al. / Virology 394 (2009) 91–98ability to bind gp120 under denaturing conditions. In contrast, both
3B3 and 16H3 mAbs can bind gp120 from subtypes B, C, and CRF01 as
well as gp140 from other subtypes under denaturing conditions by
Western blot analysis, indicating that they likely target linear
epitopes. It is striking that antibodies that were so broadly reactive
and conserved among HIV-1 subtypes and SIVcpz did not bind to Env
on virions nor neutralize HIV-1.
The recent identiﬁcation of antibodies from HIV-1 infected
subjects that do not bind to recombinant envelope yet broadly
neutralize HIV-1 strains demonstrate that native Env expresses
epitopes which are not present on HIV-1 recombinant oligomers
(Chan‐Hui et al., 2009). A strain speciﬁc human mAb 2909 was also
found unable to react with gp120 monomeric or gp140 oligomeric
forms of SF162 Env glycoprotein but bind to virions and potently
neutralized SF162 (Gorny et al., 2005). Theses studies suggest that
some mAb target quaternary structures present only on the surfaces
of intact virions. Data presented here, our work (Liao et al., 2006) and
others' works (Beddows et al., 2007; Chakrabarti et al., 2002; Crooks
et al., 2007; Kwong et al., 1998; Li et al., 2006b; Lin and Nara, 2007;
Srivastava et al., 2003; Tobin et al., 2008; Wyatt et al., 1998) in
animals, as well as immunizations in man (Gilbert et al., 2005; Lee et
al., 2001) all demonstrate that recombinant Envs, although antigenic
and binding broadly neutralizing antibodies, as yet, do not induce
sufﬁciently broad-reactive neutralizing antibodies in standard TZM-bl
cell neutralization assays. Moreover, that these speciﬁcities of
antibodies induced in mice do not capture virions demonstrates that
they will not block virions traversing mucosal surfaces. Our mAbs do
bind Env expressed on the surface of transfected T cells but do not
bind Env on the surface of HIV-1 infected T cells, implying that these
antibodies will also not mediate ADCC or other binding anti-HIV-1
activities. It is not known precisely how modiﬁcation of the cleavage
site and fusion domain alters the recombinant Envs leading to the
induction of the antibodies in this study. Nonetheless, all in the ﬁeld
would agree that these recombinant Envs are not native. However, the
92RW020, JRFL, 97ZA012, CON-S, and CON6 Envs in this study have
been previously characterized extensively for their ability to bind
sCD4 and undergo CD4 induced conformational changes to expose the
chemokine receptor binding site and thus shared antigenic similarity
to native Envs to the point of being able to bind some ligands to which
native Envs bind (Liao et al., 2006). DU123, 89.6, A.Con, B.Con, C.Con,
and US-1 SIVcpz Envs have been similarly characterized (Alam,M. and
Haynes, B., unpublished observations).
In summary, it is well known that antigenic regions are present on
HIV-1 Env and conserved on SIVcpz Env, yet these regions, although
immunogenic, are not exposed on the surface of the native Env
trimers. Nevertheless, mAbs raised against these regions can be used
as reagents to purify and characterize expressed Env proteins used in
research. Thus, combinations of these Env mAbs may be able to be
used to identify, qualify, and purify soluble Env in plasma andmucosal
ﬂuids. Finally, the ability of these antibodies to bind to recombinant
HIV-1 Envs with high afﬁnity suggest they may be of use in co-
crystallization studies of soluble Env trimers.
Materials and methods
Proteins
HIV-1 Env gp140CFI proteins (C, cleavage deﬁcient; F, fusion
deﬁcient; I, immunodominant region deletion) were puriﬁed using
Galanthus nivalis lection column from supernatant of 293T cells
infectedwith recombinant vaccinia viruses expressing Env proteins or
CHO cell lines from the Programme EVA Centre for AIDS Reagents,
NIBSC, UK, as described before (Gao et al., 2005; Liao et al., 2006).
Other recombinant HIV-1 Env proteins were obtained from NIH AIDS
Reference Reagent Repository Program (NIH, USA). Their ability to
bind soluble CD4 and various mAbs was determined by surfaceplasmon resonance (SPR) and their oligomer conformation was
conﬁrmed by blue native gel analysis as previously described. The
following Env proteins were used in ELISA andWestern blot assays to
determine the cross-reactivity: 92UG037 gp140 and 92RW020
gp140CFI (subtype A); HXB2/Bal gp140CFI, 89.6 gp120, IIIB gp120,
SF162 gp120, and JRFL gp120 or gp140CF (subtype B); 97ZA012
gp140CFI, DU123 gp140CF, and 96ZM651 gp120 (subtype C);
92UG021 gp140 (subtype D); 93TH975 gp120 and CM235 gp120
(CRF01_AE); 93BR029 gp140 (subtype F); A1.con, B.con, and C.con
gp140CF (subtype consensus); CON6 gp140CFI, CON-S gp140CF, and
CON-T gp140CF (group M consensus based on 1999, 2000, and 2003
databases, respectively); and SIVcpzUS1 gp140CF.
Immunization and generation of hybridoma cell lines
BALB/c mice were immunized with 25 μg of puriﬁed HIV-1 Env
proteins (CON6 gp140CFI or C.97ZA012 gp140CFI) in Emulsigen (MVP
Laboratories, Omaha, NE) and oCpGs (Midland Certiﬁed Reagent
Company, Inc., Midland, TX). Immunization was carried out four times
at a 2-week interval. Animals were housed in the Duke University
Animal Facility under AALAC guidelines with animal use protocols
approved by the Duke University Animal Use Committee. HIV-1
speciﬁc antibodies in mouse sera were monitored 10 days after each
immunization. Three days after the fourth immunization, splenocytes
were harvested. Hybridoma fusions were performed as previously
described using HAT (hypoxanthine, aminopterin, thymidine) sensi-
tive mouse myeloma cells, P3X63 Ag8 or NS-1 (Palker et al., 1984).
The hybridomas that secreted anti-HIV-1 Env antibodies were
identiﬁed by ELISA with autologous Env proteins after culturing for
14 days. Positive cell lines were then expanded in a large scale culture
and mAbs were puriﬁed from cell culture supernatants for further
analysis.
Western blot analysis
A panel of HIV-1 Env proteins from ﬁve subtypes (A, B, C, D, and F),
CRF01_AE, and SIVcpzUS1 was used to determine the cross-reactivity
of mAbs. Env proteins (100 ng) were separated on a reducing 10%
SDS–polyacrylamide gel and blotted onto a nitrocellulose membrane.
After blocking overnight in PBS containing 1% casein at 4 °C, the
membranes were washed and probed with mAbs in blocking buffer
(1 μg/mL). After 2 hr of incubation at room temperature, the
membranes were washed and probed with the Alexa Fluor 680
labeled goat anti-mouse IgG (H+L) antibody (1 μg/mL) in the
blocking buffer. The membranes were washed thrice with PBS
containing Tween-20 (0.05%) and the images were acquired on an
Odyssey Infrared imager.
Binding kinetics of mAbs to HIV-1 Env proteins
HIV-1 Env gp140 proteins were immobilized to about 1000 RU
using amine coupling chemistry and as described before (Alam et al.,
2007; Alam et al., 2008). Positive control V3 mAb F39F and gp41
mAbs 4E10 and 7B2 were used to assess activity of gp140 proteins
following immobilization. For comparative analyses of binding to
each Env protein, mAbs were injected at 50 μg/mL for 2 min at 30 μL/
min. For binding kinetics analyses, mAbs were injected at varying
concentrations ranging from 1.2 mg/mL to 1.5 μg/mL. Following each
cycle of binding, mAb bound surfaces were regenerated by injecting
glycine pH 2.0 for 12 sec at 50 μL/min. Due to the bivalency of the
mAbs used, binding rate constants and Kd values were derived from
global curve ﬁtting using the “Bivalent Analyte” model and
BIAevaluation 3.2 (BIAcore/GE Healthcare, Inc) as described before
(Alam et al., 2008). For comparative analyses, binding Kd was
calculated from faster rate constants (ka1 and kd1) derived from curve
ﬁtting analyses.
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MAbs were diluted in 0.1 M sodium bicarbonate (5 μg/mL) and
used to coat high-binding 96-well plates (100 μL/well) in triplicates.
The plates were kept at 4 °C overnight. After the plates were washed
three times with PBS containing 0.1% Tween-20 and blocked (150 μL/
well) with PBS containing 4% whey protein, 15% goat serum, 0.5%
Tween-20, and 0.05% NaN3 for 1 hr at room temperature, the plates
were washed twice. SF162 or BG1168 Env pseudovirus with or
without soluble CD4 was added and incubated at 37 °C for 1 hr. After
three washes, 100 μL of 0.5% Triton X-100 was added to each well to
lyse virus particles. The released P24 protein was measured with P24
detection kit (Beckman Coulter, Miami, FL).
Peptides
A number of peptides fromdifferent region of the Env proteinwere
used for epitope mapping. DP178: YTSLIHSLIEESQNQQEKNEQEL-
LELDKWASLWNWF (gp41 MPER); SP400-BaL: RVLAVERYLRDQQLL-
GIWGCSGKLICTTAVPWNASWSNKSLNKI (gp41 immunodominant
region); Bcon V3: TRPNNNTRKSIHIGPGRAFYTTGEIIGDIRQAH (gp120
V3); C.con env03 V3: TRKSIRIGPGQTFYATGDIIGDIRQAH (gp120 V3);
SP62: QQEKNEQELLELDKWASLWN (gp41 MPER containing the 2F5
epitope); P-4E10: SLWNWFNITNWLWYIK (gp41MPER containing the
4E10 epitope); DP107: NNLLRAIEAQQHLLQLTVWGIKQLQARILAVER-
YLKDQ (gp41 heptad repeat-1 region).
Full length env gene cloning
Full length env genes were ampliﬁed from genomic DNA of HIV-1
infected individuals (15313 and 17779) by nested PCR. The env genes
of a lab adapted HIV-1 MN strain (subtype B) as well as subtypes A1
and C consensus were synthesized using codon optimized sequences
(DNA 2.0, Menlo Park, CA). All env gene fragments were cloned into
pcDNA3.1/V5-His (Invitrogen, Carlsbad, CA). Positive clones were
identiﬁed by PCR.
Flow cytometry
293T/17 cells seeded in a 6-well plate were transfected using
Fugene HD (Roche Diagnostics, Indianapolis, IN) at a ratio of 12:3
(Fugene:plasmid) with the gp160 plasmids. Transfected cells were
washed 48 hrs after transfection and resuspended in PBS buffer
(Mediatech, Manassas, VA). The live/dead ﬁxable violet dead cell
stain kit was used per manufacturer's protocol (Invitrogen Mole-
cular Probes, Eugene, OR). Cells were then washed and resuspended
in XVivo15 medium (Lonza, Basel, Switzerland). Monoclonal
antibodies 3B3, 16H3, 13D5, and 2G12 (Polymun, Vienna, Austria)
were added. All antibodies had been conjugated to PE at BD
Biosciences. Cells were incubated with antibodies for 30 min at
room temperature in the dark. After washing, cells were resus-
pended in 1% paraformaldehyde (pfa; Electron Microscopy Sciences,
Hatﬁeld, PA). Cells were washed and resuspended in 1% pfa and
stored at 4°C until data acquisition. All samples were analyzed
within 24 hrs of staining and run on the FACS Canto II or FACs
Calibur (BD Biosciences, San Jose, CA).
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